TxCell to present on T Cellular Therapy for Autoimmune Diseases at the 7th National Bio-Therapy Conference 2014, China

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China.

Miguel Forte was invited to present, and will be hosted during the event, by Ferring International Center (Ferring). TxCell and Ferring are collaborating on the development of TxCell’s lead product Ovasave for inflammatory bowel diseases under an option, development and license agreement potentially worth up to EUR 76 million plus royalties.

The presentation will be entitled “T Cellular Therapy for Autoimmune Diseases: from Product Development to Market Access” and is scheduled for Saturday, October 25, 2014 at 10.40 a.m. local time.

Dr. Forte will provide an overview of the competitive positioning of TxCell’s lead product Ovasave(R), in comparison to existing third line biologic treatments and discuss current clinical evidence, as Ovasave approaches the start of the phase IIb study, to support the therapy as a potential significant new opportunity for the management of patients with Crohn’s disease in the context of emerging cellular therapy approaches. He will also discuss Col-Treg, TxCell’s second product candidate in development from its innovative proprietary ASTrIA technological platform, for the rare eye disease autoimmune uveitis, and the wider product portfolio.

Miguel Forte will also provide a wider summary of the key aspects of developing personalized cellular immunotherapy products that fulfill key market criteria, including economic viability. Other market criteria include process development activities necessary to provide a robust and transferable manufacturing process and business model establishment to ensure a benefit risk ratio that meets the expectations of all key stakeholders: investors, regulators, prescribers, payers and patients.

“Many chronic autoimmune diseases continue to present significant unmet medical needs. As TxCell is one of the most advanced companies in the field of T cell immunotherapy, it is important that we share our data and experiences on new treatment approaches to these pathologies to the benefit of the entire community,” said Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell. “The 7th National Bio-Therapy Conference is an ideal event to help position cellular therapy approaches, like TxCell’s antigen specific Treg cell-based therapies, as new value-adding treatments for the management of patients with limited current therapeutic options.”

The 7th National Bio-Therapy Conference is a global event that promotes the development of bio-therapy by providing a broad communication platform for all parties involved in the area, including clinical doctors, research scientists, experts and specialists from the bio-therapy community. The conference program is designed to cover topics including the latest clinical progress and existing challenges for immunotherapies with Treg cells, CAR-T cells, TCR-T cells and other adoptive immune and stem cell-based therapies. Related policies and regulations will also be discussed during the conference.

About TxCell
TxCell is developing innovative personalized cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary ASTrIA technology platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has completed a phase I/IIa study of its lead product candidate, Ovasave® in refractory Crohn’s disease patients and has reported good tolerability and positive clinical efficacy. The company plans to initiate a phase IIb study in the same patient population. TxCell has a strategic partnership for Ovasave with the Swiss company Ferring International Center. Listed on Euronext-Paris, TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. The company has 49 employees based at its headquarters and at its manufacturing site in Besançon.